Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:22pm, Wednesday, 11'th Mar 2026
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
01:06pm, Wednesday, 11'th Mar 2026
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years i ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% ii ; The Company's Underperforma
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Mar 2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
08:00am, Wednesday, 04'th Mar 2026
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down Following Weak Earnings
03:48am, Sunday, 01'st Mar 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
10:50am, Friday, 27'th Feb 2026
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
08:31pm, Thursday, 26'th Feb 2026
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
07:57pm, Thursday, 26'th Feb 2026
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates
06:31pm, Thursday, 26'th Feb 2026
Pacira (PCRX) came out with quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.91 per share a year ago.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
04:01pm, Thursday, 26'th Feb 2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
04:01pm, Thursday, 12'th Feb 2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
08:00am, Thursday, 12'th Feb 2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted n
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Monday, 09'th Feb 2026
BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away
06:31am, Monday, 09'th Feb 2026
Pacira BioSciences trades at distressed levels due to fears of EXPAREL patent erosion, despite strong cash flow and 78% gross margins. EXPAREL's manufacturing complexity and hospital adoption create a
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
11:02am, Tuesday, 03'rd Feb 2026
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
